ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Last trade$11.43
Day change+$0.005 (+0.04%)
Day range$10.51 – $11.77
Volume14,957
Market cap$104M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$103.82M
Price / earnings
55.24×
Price / book
3.17×
Price / sales
3.13×
EV / sales
3.13×
EV / EBITDA
14.9×
Profitability
Earnings per share
$0.21
Return on assets
3.92%
Return on equity
5.74%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.24×
Current ratio
4.61×
Quick ratio
2.5×
Cash ratio
1.69×
Cash flow
Price / cash flow
13.26×
Price / free cash flow
19.22×
Free cash flow
$5.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ICCC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$8.04M
$7.19M
$10.36M
$7.63M
$5.51M
$6.44M
$8.07M
$7.75M
Cost of revenue
$4.48M
$4.75M
$5.7M
$4.72M
$3.14M
$3.63M
$4.71M
$4.92M
Gross profit
$3.56M
$2.44M
$4.66M
$2.91M
$2.36M
$2.82M
$3.35M
$2.83M
Selling, general and administrative
$2.42M
$2.38M
$2.37M
$2.21M
$1.65M
$1.42M
$1.48M
$1.39M
Research and development
$176.77K
$119.65K
$317.69K
$758.86K
$694.31K
$831.86K
$756.85K
$819.39K
Total operating expenses
$2.6M
$502.29K
$2.69M
$2.97M
$2.34M
$2.25M
$2.24M
$2.21M
Operating income
$957.77K
$1.93M
$1.97M
-$57.96K
$20.08K
$569.56K
$1.12M
$621.4K
Interest expense
-$92.53K
-$95.67K
$0
$0
-$134.52K
-$124.8K
$0
$0
Income before taxes
$935.28K
$1.88M
$1.95M
-$2.85M
-$135.29K
$503.78K
$1.45M
$520.59K
Income taxes
-$17.24K
$45.95K
$12.52K
$3.31K
$4.46K
$1.9K
$1.9K
$6.04K
Net income
$952.51K
$1.83M
$1.94M
-$2.85M
-$139.75K
$501.88K
$1.45M
$514.56K
Net income attributable to common shareholders
$952.51K
$1.83M
$1.94M
-$2.85M
-$139.75K
$501.88K
$1.45M
$514.56K
EBITDA
$1.42M
$2.41M
$2.5M
$648.36K
$699.16K
$1.24M
$1.79M
$1.3M
Basic earnings per share
$0.10
$0.20
$0.21
-$0.31
-$0.02
$0.06
$0.16
$0.06
Diluted earnings per share
$0.10
$0.20
$0.21
-$0.31
-$0.02
$0.06
$0.16
$0.06
Recent news
Company coverage with links to the original publishers.
Zoetis (ZTS) and ImmuCell (ICCC) operate in animal health but with different profiles. Zoetis offers diversification across companion animals, livestock, and diagnostics but faces near-term headwinds from declining companion animal demand and reduced 2026 guidance. ImmuCell shows stronger recent growth with 20.9% sales increases and expanding market share in calf scours prevention, but carries higher execution risks due to narrow product focus and margin pressures during manufacturing expansion.
ImmuCell Corporation (ICCC) reported Q2 2026 product sales of $7.19 million, up 11.5% year-over-year, with earnings of 20 cents per share versus 6 cents prior year. However, gross margins contracted significantly to 33.9% from 43.7% due to lower production volumes, material quality issues, and cost reclassifications. The stock declined 8.8% post-earnings. Management highlighted strong domestic sales growth of 27.7% and increased market share for First Defense, but noted international headwinds and manufacturing challenges. The company is investing $8 million in facility expansion expected to triple capacity by end of 2027.
ImmuCell reported Q2 2025 results with improved gross margins and completed First Defense production capacity expansion, but faces ongoing FDA approval delays for Retain product, creating uncertainty in near-term growth trajectory.
The article discusses several stocks to watch heading into Wednesday, including PriceSmart, Kura Sushi, Manchester United, ImmuCell, and AZZ Inc. It provides details on the expected earnings and stock price movements for these companies.
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain®.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.